<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00962442</url>
  </required_header>
  <id_info>
    <org_study_id>AAH-LYSO</org_study_id>
    <nct_id>NCT00962442</nct_id>
  </id_info>
  <brief_title>N-Acetylcysteine in Severe Acute Alcoholic Hepatitis</brief_title>
  <official_title>N-Acetylcysteine for the Treatment of Alcoholic Hepatitis: a Belgian Multicenter Randomised Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasme University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute alcoholic hepatitis (AAH) is the most severe form of alcoholic liver disease (ALD) and&#xD;
      is associated with a high risk of dying in the short term. Corticosteroids are generally&#xD;
      recommended in patients with severe AAH, but its use is still controverted and&#xD;
      contraindicated in case of active infection or gastrointestinal bleeding. Therefore,&#xD;
      alternative therapeutic options are needed.Ethanol consumption results in the depletion of&#xD;
      endogenous antioxidant capabilities and patients with ALD have evidence of antioxidant&#xD;
      deficiencies.Due to its effects on glutathion stores restoration and as such the limitation&#xD;
      of the oxidative stress and its good tolerance and safety profile, N-acetylcysteine (NAC) is&#xD;
      an attractive agent for the treatment of AAH.In this context, we hypothesized that NAC might&#xD;
      be beneficial in severe AAH.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2000</start_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Six months survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of infections, clinical and biological parameters</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>nutritional support + N-Acétylcysteine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N-Acétylcysteine 300 mg/kg intravenously for 14 days Beside usual meals, patients must receive at least 27 kcal/kg/day enteral nutrition for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nutritional support + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo perfusion for 14 days Beside usual meals patients must receive at least 27 kcal/kg/day enteral nutrition for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-Acetylcysteine</intervention_name>
    <description>300 mg/kg for 14 days, intravenously</description>
    <arm_group_label>nutritional support + N-Acétylcysteine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Glucosé 5% perfusion for 14 days, intravenously</description>
    <arm_group_label>nutritional support + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy proven alcoholic hepatitis&#xD;
&#xD;
          -  Severe disease defined by a Maddrey score superior to 32&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Neoplastic disease compromising 6 months survival&#xD;
&#xD;
          -  HIV patients&#xD;
&#xD;
          -  Hepatorenal syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Erasme University Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <study_first_submitted>August 19, 2009</study_first_submitted>
  <study_first_submitted_qc>August 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2009</study_first_posted>
  <last_update_submitted>August 19, 2009</last_update_submitted>
  <last_update_submitted_qc>August 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>Olivier Le Moine, MD, PhD</name_title>
    <organization>Erasme University Hospital</organization>
  </responsible_party>
  <keyword>alcoholic hepatitis</keyword>
  <keyword>N-Acetylcysteine</keyword>
  <keyword>enteral nutrition</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>severe acute alcoholic hepatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

